SCHEMBL31227738

SCHEMBL31227738

COc1ccc2c(N[C@@H]3CCCN(C(=O)OC(C)(C)C)C3)nccc2c1Cl

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 2/20 0.47
▸ ANO1 Q5XXA6 1/20 0.43
▸ PIK3CA P42336 1/20 0.42
▸ USP30 Q70CQ3 2/20 0.42
▸ EHMT2 Q96KQ7 1/20 0.42
▸ PDE4B Q07343 1/20 0.41
▸ JAK2 O60674 2/20 0.41
▸ NSD2 O96028 1/20 0.41
▸ JAK1 P23458 1/20 0.41
▸ CCNT1 O60563 1/20 0.41
▸ CDK9 P50750 1/20 0.41
▸ JAK3 P52333 3/20 0.41
▸ PIM1 P11309 2/20 0.41
▸ PIM2 Q9P1W9 2/20 0.41
▸ PARP1 P09874 1/20 0.41
▸ BTK Q06187 1/20 0.41
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31227178 0.89 PIK3CD (0.47) PIK3CDPIK3CAUSP30EHMT2PDE4B
SCHEMBL31227607 0.84 PIK3CD (0.47) PIK3CDANO1PIK3CAUSP30JAK3
SCHEMBL31227853 0.84 PIK3CD (0.45) PIK3CDUSP30EHMT2PDE4BNSD2
SCHEMBL31227628 0.83 PIK3CD (0.44) PIK3CDANO1USP30EHMT2PDE4B
SCHEMBL21599048 0.82 ANO1 (0.47) PIK3CDANO1USP30PIM1PIM2
SCHEMBL31227119 0.82 ANO1 (0.51) PIK3CDANO1PIK3CAUSP30PIM1
SCHEMBL31227554 0.81 USP30 (0.48) PIK3CDANO1USP30JAK3PIM1
SCHEMBL31227846 0.81 PIK3CD (0.49) PIK3CDPIK3CAUSP30EHMT2PIM1
SCHEMBL16187368 0.79 USP30 (0.50) PIK3CDUSP30JAK2JAK3PIM1
SCHEMBL31227063 0.79 ANO1 (0.45) PIK3CDANO1USP30PDE4BJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 — — US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors MYCBP, MYC, MYCBP2 PIK3CD 3846/4885ANO1 4759/4885PIK3CA 3654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback